Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242663 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL6376667 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2853265 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8522586 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969252 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL12689155 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2857459 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15814770 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL9006 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959591 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348943-A1 | BIOPLASTIC PRODUCTION METHOD | Algae Consultant LLC | 2023-11-02 | — | — | US | disclosed |
| US-20180200753-A1 | Methods of Forming MLD Films Using Polyols With Long Carbon Backbones | ULTRATECH, INC. | 2018-07-19 | — | — | US | disclosed |
| EP-2303825-B1 | CHEMICAL TRANSFORMATION OF LIGNOCELLULOSIC BIOMASS INTO FUELS AND CHEMICALS | WISCONSIN ALUMNI RES FOUND (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9234048-B2 | Boronate-mediated delivery of molecules into cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2138048-B1 | NOVEL CARAMELS WITH A HIGH PREBIOTIC OLIGOSACCHARIDE CONTENT | UNIV SEVILLA (ES) | 2015-11-18 | — | — | EP | disclosed |
| US-9144785-B2 | Catalyst for hydrolyzing cellulose or hemicellulose and method for producing sugar-containing solution employing same | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-09-29 | — | — | US | disclosed |
| US-8795393-B2 | Method for producing biofuel using marine algae-derived galactan | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2014-08-05 | — | — | US | disclosed |
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-01 | — | — | US | disclosed |
| WO-2013110005-A1 | BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-07-25 | — | — | WO | disclosed |
| US-8492124-B2 | Prebiotic formulations and methods of use | RITTER PHARMACEUTICALS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120053355-A1 | Method for Producing Biofuel Using Marine Algae-Derived Galactan | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20070108057-A1 | Enzyme immobilization for electroosmotic flow | NATIONAL SCIENCE FOUNDATION | 2007-05-17 | — | — | US | disclosed |
| US-7172682-B2 | Enzyme immobilization for electroosmotic flow | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070000781-A1 | ENZYME IMMOBILIZATION FOR ELECTROOSMOTIC FLOW | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070000781-A1 | ENZYME IMMOBILIZATION FOR ELECTROOSMOTIC FLOW | MGAM, PNKP, AGL | MEN1 4277/4885KMT2A 1073/4885PYGB 565/4885 |
| US-20120053355-A1 | Method for Producing Biofuel Using Marine Algae-Derived Galactan | AGL, MGAM, GALK1 | MEN1 2053/4885KMT2A 1388/4885PYGB 1230/4885 |
| US-20130196433-A1 | Boronate-Mediated Delivery of Molecules into Cells | BCAP31, PHAX, BTD | MEN1 1395/4885KMT2A 3901/4885PYGB 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.